BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17176883)

  • 1. [The role of GATA1 mutation in acute megakaryocytic leukemia].
    Ito E
    Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
    [No Abstract]   [Full Text] [Related]  

  • 2. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
    Splendore A; Magalhães IQ; Pombo-de-Oliveira MS
    Hum Mutat; 2005 Oct; 26(4):390-2. PubMed ID: 16134163
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.
    Heald B; Hilden JM; Zbuk K; Norton A; Vyas P; Theil KS; Eng C
    Nat Clin Pract Oncol; 2007 Jul; 4(7):433-8. PubMed ID: 17597708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
    Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down syndrome and GATA1-related transient leukemia.
    Sandoval C; Pine SR
    J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
    [No Abstract]   [Full Text] [Related]  

  • 7. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant.
    Shimizu R; Kobayashi E; Engel JD; Yamamoto M
    Genes Cells; 2009 Sep; 14(9):1119-31. PubMed ID: 19682090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
    Satgé D
    Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.
    Inaba H; Londero M; Maurer SH; Onciu M; Ge Y; Taub JW; Rubnitz JE; Raimondi SC
    J Clin Oncol; 2011 Mar; 29(9):e230-3. PubMed ID: 21205752
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular insights into Down syndrome-associated leukemia.
    Vyas P; Crispino JD
    Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The molecular mechanism of leukemogenesis in Down syndrome-related acute megakaryocytic leukemia].
    Ito E; Toki T
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():136-40. PubMed ID: 17476742
    [No Abstract]   [Full Text] [Related]  

  • 14. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
    Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
    Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome.
    Xu G; Kanezaki R; Toki T; Watanabe S; Takahashi Y; Terui K; Kitabayashi I; Ito E
    Leukemia; 2006 Jun; 20(6):1002-8. PubMed ID: 16628190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21.
    Stepensky P; Brooks R; Waldman E; Revel-Vilk S; Izraeli S; Resnick I; Weintraub M
    Pediatr Blood Cancer; 2010 Jul; 54(7):1048-9. PubMed ID: 20108342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.
    Hitzler J; Zipursky A
    Leuk Res; 2005 Nov; 29(11):1239-40. PubMed ID: 15925405
    [No Abstract]   [Full Text] [Related]  

  • 19. GATA1s goes germline.
    Mundschau G; Crispino J
    Nat Genet; 2006 Jul; 38(7):741-2. PubMed ID: 16804537
    [No Abstract]   [Full Text] [Related]  

  • 20. [GATA1 analysis in myeloproliferative disorders associated to trisomy 21].
    Fuster Soler JL; Norton A; Galera Miñarro A; Bermúdez Cortés M; Llinares Riestra ME; Ortuño Giner F
    An Pediatr (Barc); 2011 Jan; 74(1):31-7. PubMed ID: 20870473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.